PRCT
PROCEPT BioRobotics Corporation Common Stock
stockNASDAQ
based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company's first product, the aquabeam system delivering aquablation therapy, is the world's first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 17.25 | 2026-09-28 | +2.85% | -2.706 |
| 1M | 22.76 | 2026-09-04 | -22.05% | 0.347 |
| 3M | 21.21 | 2026-07-06 | -16.36% | 0.220 |
| 6M | 23.78 | 2026-04-06 | -25.39% | 0.351 |
| 1Y | 35.24 | 2025-10-06 | -49.66% | 0.794 |
| 2Y | 72.66 | 2024-10-04 | -75.58% | — |
| 5Y | 38.68 | 2021-10-05 | -54.13% | 1.215 |
PROCEPT BioRobotics Corporation Common Stock (NASDAQ:PRCT) stock price today is $17.74, and today's volume is 181,987. PRCT is up 3.386% today. The 30 day average volume is 1.26M. PRCT market cap is $1.02B with 57.27M shares outstanding.